人类胰腺癌的胃肠多肽受体表达

Expression of Receptors for Gut Peptides in Human Pancreatic Adenocarcinoma and Normal Pancreas

目的:了解胃肠多肽受体的表达在胰腺癌发生过程中的重要意义。方法:用储磷放射自显影显示和比较正常胰腺(n=10)及胰腺导管癌(n=12)的胆囊收缩素(CCK)、蛙皮素(BBS)、胰泌素、肠血管活性多肽(VIP)及生长抑素(SST)受体。结果:与正常胰腺比较,胰腺癌细胞上的多肽受体表达发生了很大变化。存在于正常胰腺腺泡细胞上的CCK、BBS、胰泌素受体在胰腺癌细胞上明显减少或消失。反之,在多数病例的胰腺癌细胞上检测到在正常胰腺不能显出的肠血管活性多肽及生长抑素受体。结论:本研究为胰腺癌的激素治疗提供了有价值的依据。

Background/Aims: Gut hormones that modulate the growth of normal pancreas may also modulate the growth of cancers originating from pancreas. This study visualized and compared the receptors for cholecystokinin (CCK), bombesin (BBS), secretin, vasoactive intestinal peptide (VIP) and somatostatin (SST) in tissue sections of normal hman pancreas (w = 10) and pancreatic ductal adenocarcinomas (n = 12) with storage phosphor autoradiography. CCK-B receptors, present in all normal pancreas, were not detected in any of the pancreatic cancers. BBS receptors were visualized in normal pancreas but they were absent in 10 of 12 pancreatic cancers. In 5 of 12 pancreatic cancers, receptors for secretin were visualized, while binding for secretin was present in all normal pancreas. Conversely, no specific binding of VIP and SST were detected in normal pancreas but they were identified in 3 of 12 and all specimens of pancreatic cancer. It is concluded that the expression of gut peptide receptors in pancreatic cancer differs from that in normal pancreas. Receptors for these peptides are present only in a minority of pancreatic cancer specimens.